Table 3. Clinico-pathological characteristics of patients with metastatic lung cancer with their respective CTC counts.
|
ISET
|
CellSearch | ||||||
|---|---|---|---|---|---|---|---|
| Patients | Age a | Sex | Histology | TNM stage | CTC/7.5 ml | Atypical cells/7.5 ml | C/7.5 ml |
| L1 | 61 | M | IAb | pT2N0M1 | 23 | 7 | 1 |
| L2 | 63 | F | SC | pT2N2M1 | 20 | 28 | 3 |
| L3 | 38 | F | EC | pT3N3M1 | 12 | 3 | 1 |
| L4 | 56 | F | IA | T3N3M1 | 3 | 4 | 2 |
| L5 | 59 | M | IA | T4N3M1 | 5 | 9 | 5 |
| L6 | 56 | M | IA | T3N2M1 | 2 | 2 | 0 |
| L7 | 55 | F | IAb | T2N3M1 | >100 | 0 | 13 500 |
| L8 | 72 | M | NE | pT3N0M1 | 16 | 10 | 0 |
| L9 | 67 | F | IA | pT2N2M1 | 5 | 22 | 1 |
| L10 | 60 | M | IA | T3N3M1 | 2 | 2 | 0 |
| L11 | 60 | M | IA | T2N2M1 | 14 | 7 | 46 |
| L12 | 51 | F | IA | pT2N0M1 | 2 | 2 | 0 |
| L13 | 56 | M | IA | T2N2M1 | 1 | 7 | 0 |
| L14 | 61 | F | IA | pT2N0M1 | 2 | 9 | 0 |
| L15 | 38 | M | IA | T4N2M1 | 1 | 2 | 0 |
| L16 | 54 | M | EC | pT4N2M1 | 1 | 0 | 0 |
| L17 | 51 | F | IA | T2N2M1 | 17 | 28 | 1 |
| L18 | 61 | M | IA | T2N2M1 | 12 | 53 | 0 |
| L19 | 42 | M | IAc | T2N0M? | 6 | 5 | 0 |
| L20 | 54 | F | IA | pT2N2M0 | 7 | 46 | 0 |
Abbreviations: CTC=circulating tumour cell; EC=infiltrative epidermoid carcinoma; F=female; IA=infiltrative adenocarcinoma; M=male; NE=large cell neuroendocrine carcinoma; SC=sarcomatoid carcinoma with giant cells; TNM=tumour node metastasis.
a
Age (years) at the moment of CTC analysis.
b
Poorly differentiated.
c
Bronchoalveolar.